Pricey New HCV, Cancer Drugs Push Up Japan’s Health Care Costs
Executive Summary
Japan has reported big rises in drug costs covered by its national health insurance scheme, driven in large part by hepatitis C and cancer, adding weight to ongoing discussions of possible new cost containment measures.
You may also be interested in...
Industry Fears Realized As Japan Moves To Annual Price Cuts
Against the protests of the innovative pharma industry, Japan is pushing ahead with an overhaul of its drug reimbursement pricing system that will include a shift to annual price revisions.
Japan Delays Keytruda Pricing Amid PD-1 Cost Concerns
Regulatory authorities in Japan have put back the granting of a reimbursement price to Keytruda under the national health insurance system amid rising worries over the cost of new cancer immunotherapies, delaying the launch of the product for now.
EFPIA Urges Japan To Consider New Funding Models
Amid intensifying official scrutiny of rising drug costs, the European industry federation EFPIA would like Japan to focus more on the measuring the actual benefits and health outcomes of new therapies, helped by new approaches and technology.